Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Millendo gets $49.5mm in financing concurrent with OvaScience merger closing

Executive Summary

Concurrent with the closing of its reverse merger with OvaScience Inc., Millendo Therapeutics Inc. raised $49.5mm in a financing from Great Point Partners, New Enterprise Associates, Frazier Healthcare Partners, Roche Venture Fund, Innobio (managed by Bpifrance), Osage University Partners, Altitude Life Science Ventures, Adams Street Partners, and Longwood Fund. Jefferies and Leerink Partners were the placement agents. Following the merger, Millendo will become a publicly traded entity.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies